Last reviewed · How we verify
Intravenous racemic ketamine
At a glance
| Generic name | Intravenous racemic ketamine |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Repeated Neurocognitive Measurements in Depressed Patients (PHASE1, PHASE2)
- Intravenous Ketamine for Treatment-Resistant Depression (PHASE2)
- Chart Review of Patients Undergoing Ketamine Treatments for Depression
- Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users (PHASE1)
- Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants (PHASE1)
- Ketamine + Mindfulness for Depression (PHASE1, PHASE2)
- Repeated Neurocognitive Measurements in Depressed Patients (PHASE1, PHASE2)
- Imaging Neural Correlates of Ketamine Using PET/MR (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |